NewsRoom

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

201020092008

Jun 14, 2017
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Jun 5, 2017
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
May 31, 2017
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma
May 18, 2017
Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Data to be presented at ASCO and EHA in June; Abstracts now available online
May 4, 2017
MEI Pharma Reports Third Quarter Fiscal Year 2017 Results
Apr 3, 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Mar 28, 2017
MEI Pharma to Present at Needham Healthcare Conference
Live Webcast from New York on April 4th
Mar 14, 2017
MEI Pharma to Present at Oppenheimer Healthcare Conference
Live Webcast from New York on March 21st
Feb 8, 2017
MEI Pharma Reports Second Quarter Fiscal Year 2017 Results
Company Begins Calendar Year with $55 Million in Cash
Dec 5, 2016
Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016
Nov 17, 2016
MEI Pharma to Host Annual Meeting of Stockholders
Live Webcast from San Diego on December 1st
Nov 9, 2016
MEI Pharma Reports First Quarter Fiscal Year 2017 Results
Quarter Highlighted by Breakthrough Therapy Designation and Global Strategic Partnership for Pracinostat
Nov 7, 2016
MEI Pharma to Present at Stifel Healthcare Conference
Live Webcast from New York on November 15th
Nov 3, 2016
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
Data to be presented on December 3, 2016; Abstract now available online
Sep 6, 2016
MEI Pharma Reports Fiscal Year 2016 Results
Company Now Well Positioned with Fully Funded, Phase III-Ready Asset, Emerging Pipeline and Strong Cash Balance
 

rss